# Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

> **NCT02979431** · PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 180 (actual)

## Conditions studied

- Respiratory Syncytial Virus Lower Respiratory Tract Infection

## Interventions

- **BIOLOGICAL:** ALX-0171 3.0 mg/kg
- **BIOLOGICAL:** ALX-0171 6.0 mg/kg
- **BIOLOGICAL:** ALX-0171 9.0 mg/kg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02979431
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2018-05-25
- **Final completion:** 2018-05-25
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2019-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979431, "Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02979431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*